Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States of America.
PLoS One. 2010 Oct 18;5(10):e13428. doi: 10.1371/journal.pone.0013428.
Vitamin D binding protein-macrophage activating factor (DBP-maf) is a potent inhibitor of tumor growth. Its activity, however, has been attributed to indirect mechanisms such as boosting the immune response by activating macrophages and inhibiting the blood vessel growth necessary for the growth of tumors.
In this study we show for the first time that DBP-maf exhibits a direct and potent effect on prostate tumor cells in the absence of macrophages. DBP-maf demonstrated inhibitory activity in proliferation studies of both LNCaP and PC3 prostate cancer cell lines as well as metastatic clones of these cells. Flow cytometry studies with annexin V and propidium iodide showed that this inhibitory activity is not due to apoptosis or cell death. DBP-maf also had the ability to inhibit migration of prostate cancer cells in vitro. Finally, DBP-maf was shown to cause a reduction in urokinase plasminogen activator receptor (uPAR) expression in prostate tumor cells. There is evidence that activation of this receptor correlates with tumor metastasis.
These studies show strong inhibitory activity of DBP-maf on prostate tumor cells independent of its macrophage activation.
维生素 D 结合蛋白-巨噬细胞激活因子(DBP-maf)是一种强效的肿瘤生长抑制剂。然而,其活性归因于间接机制,例如通过激活巨噬细胞来增强免疫反应,以及抑制肿瘤生长所需的血管生长。
在这项研究中,我们首次表明 DBP-maf 在没有巨噬细胞的情况下对前列腺肿瘤细胞表现出直接而强效的作用。DBP-maf 在 LNCaP 和 PC3 前列腺癌细胞系以及这些细胞的转移性克隆的增殖研究中表现出抑制活性。用 Annexin V 和碘化丙啶进行的流式细胞术研究表明,这种抑制活性不是由于细胞凋亡或死亡引起的。DBP-maf 还能够抑制前列腺癌细胞的体外迁移。最后,DBP-maf 被证明能够导致前列腺肿瘤细胞中尿激酶纤溶酶原激活物受体(uPAR)表达减少。有证据表明,该受体的激活与肿瘤转移相关。
这些研究表明 DBP-maf 对前列腺肿瘤细胞具有强烈的抑制活性,独立于其巨噬细胞激活。